Future studies aimed at elucidating how this compound binds to the estrogen receptors and the exact mechanism by which bonediol activates Nrf2-ARE will be beneficial to development of a potential new prostate cancer therapeutic. This evidence concerns the gene NFE2L2 and prostate carcinoma.